Matches in Wikidata for { <http://www.wikidata.org/entity/Q96827434> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q96827434 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q96827434 description "scientific article published on 01 July 2020" @default.
- Q96827434 description "wetenschappelijk artikel" @default.
- Q96827434 description "наукова стаття, опублікована 1 липня 2020" @default.
- Q96827434 name "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 name "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 type Item @default.
- Q96827434 label "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 label "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 prefLabel "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 prefLabel "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 P1433 Q96827434-2C4CF93B-382D-48C7-8475-7C15F71E5C97 @default.
- Q96827434 P1476 Q96827434-490F07D5-09CC-4CE1-9337-32BF676D9532 @default.
- Q96827434 P2093 Q96827434-1D904B6B-4B0C-4AAD-A952-C363DDBA4952 @default.
- Q96827434 P2093 Q96827434-6ED01152-7605-4EDF-BC82-1190142CFAF5 @default.
- Q96827434 P2093 Q96827434-73164BB1-6E69-47BC-804D-794F6C7A9E40 @default.
- Q96827434 P2093 Q96827434-91D07F17-F135-45BD-A925-AA043F42050E @default.
- Q96827434 P2093 Q96827434-993E5548-0F63-4BCF-B064-98F5ED94DF7C @default.
- Q96827434 P2093 Q96827434-9F3A1383-3AC6-4FD4-8453-CFEC8CF786D5 @default.
- Q96827434 P2093 Q96827434-B9861469-F4BA-4F03-9600-C343E07F52B1 @default.
- Q96827434 P2093 Q96827434-EE0EB669-290A-4009-9C52-9B86BAC08FE5 @default.
- Q96827434 P2093 Q96827434-F448580C-42B2-4FE1-A877-72DC8396E8CC @default.
- Q96827434 P31 Q96827434-3082F626-AFDA-4764-AA13-9FD3E45A7171 @default.
- Q96827434 P356 Q96827434-40F30645-BCCA-4188-959E-14584E3DE34B @default.
- Q96827434 P50 Q96827434-137DCA9A-CC84-44DA-8410-D21ECC25B98A @default.
- Q96827434 P577 Q96827434-4CACF6B7-1EDC-442A-99CC-F52F79158C9D @default.
- Q96827434 P698 Q96827434-48283E66-E0BB-4537-B568-D5A84CD0ACF6 @default.
- Q96827434 P921 Q96827434-8DC1883D-AEE4-4804-829F-133A2202D3CA @default.
- Q96827434 P921 Q96827434-8F4AC10C-0D81-4595-92E0-F44297A162B5 @default.
- Q96827434 P932 Q96827434-E528BB8B-73D7-4481-8E8F-DD56FF278E72 @default.
- Q96827434 P356 CAM4.3209 @default.
- Q96827434 P698 32608149 @default.
- Q96827434 P1433 Q27724564 @default.
- Q96827434 P1476 "Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma" @default.
- Q96827434 P2093 "Denise Grathwohl" @default.
- Q96827434 P2093 "Franziska Krummenast" @default.
- Q96827434 P2093 "Hans-Benno Leicht" @default.
- Q96827434 P2093 "Hermann Einsele" @default.
- Q96827434 P2093 "Katharina Meckel" @default.
- Q96827434 P2093 "Katharina Nickel" @default.
- Q96827434 P2093 "Klaus M Kortüm" @default.
- Q96827434 P2093 "Maximilian J Steinhardt" @default.
- Q96827434 P2093 "Xiang Zhou" @default.
- Q96827434 P31 Q13442814 @default.
- Q96827434 P356 "10.1002/CAM4.3209" @default.
- Q96827434 P50 Q89647082 @default.
- Q96827434 P577 "2020-07-01T00:00:00Z" @default.
- Q96827434 P698 "32608149" @default.
- Q96827434 P921 Q18936 @default.
- Q96827434 P921 Q422252 @default.
- Q96827434 P932 "7433809" @default.